Get the Stockscreener App
12.84
0.63%
0.08
Climb Bio Inc stock is traded at $12.84, with a volume of 665.91K.
It is up +0.63% in the last 24 hours and up +0.71% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
See More
Previous Close:
$12.76
Open:
$12.89
24h Volume:
665.91K
Relative Volume:
0.55
Market Cap:
$735.26M
Revenue:
-
Net Income/Loss:
$-52.79M
P/E Ratio:
-16.48
EPS:
-0.7789
Net Cash Flow:
$-53.49M
1W Performance:
+1.10%
1M Performance:
+0.71%
6M Performance:
+155.78%
1Y Performance:
+767.57%
1-Day Range:
$12.25
$12.99
1-Week Range:
$12.14
$13.22
52-Week Range:
$1.36
$14.41
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
12.84 | 735.26M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Mizuho | Outperform |
| Mar-24-26 | Initiated | B. Riley Securities | Buy |
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Mar-05-26 | Initiated | Wedbush | Outperform |
| Feb-13-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
Frontier tech research, news & data - MLQ.ai
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment - Moomoo
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in FocusWeak Sell Signals - DonanımHaber
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineNegative Surprise Momentum - dars.gov.et
Climb Bio, Inc. advances CD19-based approach to preserve protective antibody function - Traders Union
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges HigherPost-Announcement Reaction - DonanımHaber
Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Nigeria
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Climb Bio Inc. (CLYM) Q1 2026 Earnings: EPS Beat Partially Offsets Market Skepticism as Pre-Revenue Biotech Navigates Clinical ProgressDividend Earnings Report - dars.gov.et
Climb Bio Appoints Breanna O’Reilly to Board - The Globe and Mail
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com UK
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Nigeria
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com India
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
CLYM Q1 2026 Earnings: Narrowed Loss Beat Expectations as Biotech Continues Pipeline DevelopmentProfit Margin Analysis - dars.gov.et
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Dynamic Index - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Climb Bio Q1 2026 Earnings: Bottom-Line Beat Provides Positive MomentumEPS Surprise History - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio, Inc. Actuals & Estimates (NASDAQ:CLYM) - TradingView
NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients - Traders Union
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Climb Bio stock price target reiterated at $20 by H.C. Wainwright - Investing.com UK
CLYM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Climb Bio stock price target reiterated at $20 by H.C. Wainwright By Investing.com - Investing.com India
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):